Healthcare Industry News: Vacutainer
News Release - November 28, 2006
Rheologics Launches Blood Viscosity Test ServicesEXTON, PA--(Healthcare Sales & Marketing Network)--Nov 28, 2006 -- Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc. (Other OTC:RTGI.PK ), ("Rheologics"), the leader in the study of blood viscosity and its relationship to cardiovascular disease, is pleased to announce that its Laboratory Services unit has launched its Whole Blood Viscosity (WBV) testing program for physicians.
For general practitioners and internists, knowing the viscosity of their patients' blood provides a critical tool in evaluating the efficiency and health of a cardiovascular system. The role that blood viscosity plays in cardiovascular health is substantial. Since the cardiovascular system is a closed system, the viscosity or thickness of what the heart is pumping directly affects the heart's efficiency and the damage done to the arteries by blood flow.
As part of the program, patients' blood specimens are drawn at their physicians' offices into standard lavender-top Vacutainers (EDTA) and shipped overnight in a cold pack to Rheologics' laboratory facility in Exton, Pennsylvania. Rheologics provides physicians with the specimen collection kits used for convenient packing and shipping. Test results include a graph of the WBV Profile of the patient's blood against a benchmark as well as an interpretive guide. The results are typically provided within 24 hours.
Blood is a complex, shear-thinning fluid. It can be several times thicker when the heart is at diastole than at systole (from the beginning to the end of each heartbeat) -- as much ten times thicker in patients with severely pathological blood flow. Blood viscosity affects not only how hard the heart has to work to circulate the blood, but also affects the level of stress, injury and inflammation the blood causes to the arteries. The thicker the blood is the more injury it causes to the arteries, resulting in arterial remodeling, hardening of the arteries, growth of atherosclerotic lesions and plaque rupture.
Daniel Cho, President of Rheologics, Inc., said, "The definitive role that elevated blood viscosity plays in the onset and acceleration of cardiovascular disease will become more evident through further research and testing. Today, whole blood viscosity is a basic physiological parameter that can aid physicians in the interpretation their patients' cardiovascular disease conditions. Tomorrow, the market for blood viscosity testing may be equal to or larger than to the cholesterol testing market, especially since blood viscosity has the potential to quantify the root case of cardiovascular disease."
The U.S. market for the LDL testing is estimated at 65 million tests per year, while the U.S. market for HDL tests is estimated at 100 million tests per year. Cardiovascular disease is one of the leading causes of death in the United States, affecting more than 62 million Americans and claiming the lives of nearly one million people in the U.S. per year. Globally, over 17 million people die from vascular diseases, mostly heart attacks and strokes.
Rheologics Laboratory Services uses an innovative scanning capillary viscometer called the RheologŪ to measure the biophysical properties of circulating blood and provide a complete and accurate WBV Profile. The RheologŪ captures a patient's continuous blood viscosity over a broad range of shear rates that mimic blood flow in the human vascular system.
The RheologŪ is an FDA IDE-exempt device approved for research and for providing additional information in the interpretation of a disease condition and therefore is not covered by insurance plans. Physicians bill their patients or their caregivers for this service.
About Rheologics Technologies, Inc.
Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.
Source: Rheologics Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.